Natural killer cells license dendritic cell cross-presentation of B lymphoma cell - Associated antigens

被引:14
作者
Dao, T [1 ]
Gomez-Nunez, M [1 ]
Antczak, C [1 ]
Kappel, B [1 ]
Jaggi, JS [1 ]
Korontsvit, T [1 ]
Zakhaleva, V [1 ]
Scheinberg, DA [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA
关键词
D O I
10.1158/1078-0432.CCR-05-0975
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Presentation of exogenous antigen by MHC class I molecules, or cross-presentation, is a property of dendritic cells, which is considered crucial for the priming of cytotoxic T-cell response to tumor antigens. However, the precise mechanisms of this process are not fully understood, Experimental Design and Results: We show here in a human in vitro system, using B lymphoma cells as a tumor model, that the cross-presentation of cell-associated antigens to T cells by dendritic cells requires "help" from natural killer cells. When autologous dendritic cells that had taken up apoptotic B lymphoma cells and induced to a fully mature state were used to stimulate nonadherent cells of peripheral blood mononuclear cells from healthy donors, they induced strong cytotoxicity against B lymphoma cells in a HLA-A0201-restricted manner. The cells failed to induce cytotoxicity, however, when purified T cells were used as effector cells. Depletion of CD56(+) cells, but not CD14(+) or CD19(+) cells, abrogated the cytotoxicity of non- adherent cells, showing that the help was provided by natural killer cells. Further, when natural killer cells were present in the cultures, a strong and persistent production of interleukin-18, but not interleukin-12 and interleukin-15, was observed. Blocking interleukin-18 significantly reduced the cytotoxicity of nonadherent cells against B lymphoma cells. Conclusions: These results suggest that capture of tumor cells and a full maturation status of dendritic cells are not sufficient to cross-prime CD8 Tcells. Effective cross-priming requires further activation of dendritic cells by natural killer cells and an abundant production of interleukin-18, which, along with other yet undefined mechanisms, contribute to the generation of CTL response against B-cell lymphoma.
引用
收藏
页码:8763 / 8772
页数:10
相关论文
共 59 条
[1]   Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells [J].
Ackerman, AL ;
Kyritsis, C ;
Tampé, R ;
Cresswell, P .
NATURE IMMUNOLOGY, 2005, 6 (01) :107-113
[2]   Maturation matters: Importance of maturation for antitumor immunity of dendritic cell vaccines [J].
Adams, S ;
O'Neill, D ;
Bhardwaj, N .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) :3834-3835
[3]   Targeting apoptotic tumor cells to FcγR provides efficient and versatile vaccination against tumors by dendritic cells [J].
Akiyama, K ;
Ebihara, S ;
Yada, A ;
Matsumura, K ;
Aiba, S ;
Nukiwa, T ;
Takai, T .
JOURNAL OF IMMUNOLOGY, 2003, 170 (04) :1641-1648
[4]   Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells [J].
Albert, ML ;
Jegathesan, M ;
Darnell, RB .
NATURE IMMUNOLOGY, 2001, 2 (11) :1010-1017
[5]   Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].
Albert, ML ;
Sauter, B ;
Bhardwaj, N .
NATURE, 1998, 392 (6671) :86-89
[6]   Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies [J].
Bae, J ;
Martinson, JA ;
Klingemann, HG .
CLINICAL CANCER RESEARCH, 2005, 11 (04) :1629-1638
[7]   Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells [J].
Berard, F ;
Blanco, P ;
Davoust, J ;
Neidhart-Berard, EM ;
Nouri-Shirazi, M ;
Taquet, N ;
Rimoldi, D ;
Cerottini, JC ;
Banchereau, J ;
Palucka, AK .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (11) :1535-1543
[8]   CROSS-PRIMING FOR A SECONDARY CYTOTOXIC RESPONSE TO MINOR H-ANTIGENS WITH H-2 CONGENIC CELLS WHICH DO NOT CROSS-REACT IN CYTOTOXIC ASSAY [J].
BEVAN, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1976, 143 (05) :1283-1288
[9]   In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination [J].
Bonifaz, LC ;
Bonnyay, DP ;
Charalambous, A ;
Darguste, DI ;
Fujii, SI ;
Soares, H ;
Brimnes, MK ;
Moltedo, B ;
Moran, TM ;
Steinman, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (06) :815-824
[10]  
CAMPBELL MJ, 1987, J IMMUNOL, V139, P2825